New drug shows promise for tough lung cancers

NCT ID NCT04940325

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and look for markers that predict who benefits most. The goal is to find a better option for patients who have run out of standard therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, 94010, France

  • Gustave Roussy

    Villejuif, 94805, France

  • Hospices Civils de Lyon - Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69310, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Tenon

    Paris, 75970, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut de Cancérologie, CHRU Morvan de Brest

    Brest, 29200, France